Compass Pathways PLC CMPS
Institutional shares held
57.2 Million
3.08M
calls
778K
puts
Total value of holdings
$488M
$26.3M
calls
$6.64M
puts
Market Cap
$363M
42,522,400
Shares Out.
Institutional ownership
134.46%
# of Institutions
187
We take great care to ensure that the data presented and summarized in this overview for COMPASS Pathways plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CMPS
View all-
Rtw Investments, LP New York, NY8.71MShares$74.4 Million0.99% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.86MShares$67.1 Million2.12% of portfolio
-
Gmt Capital Corp Atlanta, GA2.84MShares$24.3 Million1.1% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.72MShares$23.2 Million0.01% of portfolio
-
Tang Capital Management LLC San Diego, CA2.2MShares$18.8 Million0.85% of portfolio
-
Ubs Group Ag2.14MShares$18.3 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl2.12MShares$18.1 Million0.13% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT1.73MShares$14.8 Million0.6% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA1.66MShares$14.2 Million1.2% of portfolio
-
Jefferies Financial Group Inc. New York, NY1.38MShares$11.8 Million0.06% of portfolio
Latest Institutional Activity in CMPS
Top Purchases
Top Sells
About CMPS
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Insider Transactions at CMPS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 01
2025
|
Kabir Nath Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,366
-2.8%
|
$25,464
$4.34 P/Share
|
|
Mar 11
2025
|
Kabir Nath Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
92,000
+28.78%
|
-
|
|
Mar 11
2025
|
Teri Loxam Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+23.09%
|
-
|
|
Mar 03
2025
|
Teri Loxam Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,468
-7.12%
|
$13,404
$3.67 P/Share
|
|
Feb 03
2025
|
Kabir Nath Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,516
-10.26%
|
$62,064
$4.31 P/Share
|
|
Oct 24
2024
|
George Jay Goldsmith > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
776,565
-19.76%
|
-
|
|
Oct 24
2024
|
George Jay Goldsmith > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
776,565
-19.75%
|
-
|
|
Oct 24
2024
|
Ekaterina Malievskaia > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
776,565
-19.75%
|
-
|
|
Oct 24
2024
|
Ekaterina Malievskaia > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
776,565
-19.76%
|
-
|
|
Sep 26
2024
|
Life Sciences N.V. Atai |
SELL
Open market or private sale
|
Indirect |
2,660,000
-27.81%
|
$15,960,000
$6.05 P/Share
|
|
Aug 01
2024
|
Kabir Nath Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,064
-4.46%
|
$42,384
$6.88 P/Share
|
|
Aug 01
2024
|
Annalisa Jenkins Director |
SELL
Payment of exercise price or tax liability
|
Direct |
161
-0.82%
|
$966
$6.88 P/Share
|
|
May 21
2024
|
George Jay Goldsmith > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,900
-0.23%
|
$62,300
$7.91 P/Share
|
|
May 21
2024
|
George Jay Goldsmith > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
8,900
-0.23%
|
$62,300
$7.91 P/Share
|
|
May 21
2024
|
Ekaterina Malievskaia > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,900
-0.23%
|
$62,300
$7.91 P/Share
|
|
May 21
2024
|
Ekaterina Malievskaia > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
8,900
-0.23%
|
$62,300
$7.91 P/Share
|
|
May 20
2024
|
George Jay Goldsmith > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
6,704
-0.17%
|
$46,928
$7.89 P/Share
|
|
May 20
2024
|
George Jay Goldsmith > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
6,703
-0.17%
|
$46,921
$7.89 P/Share
|
|
May 20
2024
|
Ekaterina Malievskaia > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
6,703
-0.17%
|
$46,921
$7.89 P/Share
|
|
May 20
2024
|
Ekaterina Malievskaia > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
6,704
-0.17%
|
$46,928
$7.89 P/Share
|
Last 12 Months Summary
Buy / Acquisition
117K
Shares
From
2
Insiders
| Grant, award, or other acquisition | 117K shares |
|---|
Sell / Disposition
26.4K
Shares
From
2
Insiders
| Payment of exercise price or tax liability | 26.4K shares |
|---|